Clinical Trial Update: Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy, safety and tolerability of long-acting cabotegravir plus long-acting rilpivirine in adults with HIV-1 infection. Results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Cabotegravir long-acting (cabotegravir)
• Rilpivirine long-acting (rilpivirine)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-06-11